Institute seminar February 13th Jostein Dahle

Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B (2025)
Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes
Commun Biol, 8 (1), 992
DOI 10.1038/s42003-025-08413-0, PubMed 40610675

Hurley JH, Coyne AN, Miączyńska M, Stenmark H (2025)
The expanding repertoire of ESCRT functions in cell biology and disease
Nature, 642 (8069), 877-888
DOI 10.1038/s41586-025-08950-y, PubMed 40562928

Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA (2025)
Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis
J Transl Med, 23 (1), 672
DOI 10.1186/s12967-025-06644-7, PubMed 40528241

Patel D, Tiusanen V, Karttunen K, Pihlajamaa P, Sahu B (2025)
Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes
Commun Biol, 8 (1), 992
DOI 10.1038/s42003-025-08413-0, PubMed 40610675

Pagui ECK, Brant SB, Svendsen K, Frigessi A, Helland Å, Thoresen S, Jonasson C (2025)
Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second-Line Treatment of Advanced Non-Small Cell Lung Cancer
Pharmacoepidemiol Drug Saf, 34 (7), e70181
DOI 10.1002/pds.70181, PubMed 40552731

Stålberg SM, Silwal-Pandit L, Hamfjord J, Nebdal DJH, Lehtiö J, Lingjærde OC, Skålhegg BS, Kure EH (2025)
Elevated KRAS protein level is associated with better survival in pancreatic cancer
BMC Cancer, 25 (1), 1080
DOI 10.1186/s12885-025-14461-w, PubMed 40596921